A Leishmaniose Tegumentar é uma doença infecciosa negligenciada, endêmica em 13 países da América, tendo o Brasil como responsável por 96% das notificações. O tratamento de primeira linha antimoniato N-metil-glucamina (Glucantime), droga parenteral e com várias contraindicações, que dificulta seu uso regiões isoladas do nosso país, justamente onde a maior incidência ocorre. Em 2020 Ministério S...

Background: The adverse effects and increased resistance of drugs necessities the discovery novel combination therapy. Objectives: This study aimed to examine Artemisinin plus glucantime or shark cartilage extract on Iranian strain Leishmania major (MRHO/IR/75/ER) in vitro vivo. Methods: In experiments, their different concentrations (3.12 - 400 µg/mL) promastigotes, amastigotes, un-infected ma...

In this study we examined enhancement effects of Artemisinin plus Glucantime and shark cartilage extract, on promastigotes and amastigotes of L.infantum in in vitro condition.The toxicity of artemisinin, glucantime and shark cartilage extract on the L. infantum promastigotes and amastigote-infected macrophages was evaluated using MTT assay. The role of these drugs in inducing apoptosis in proma...

BACKGROUND This study was designed to detect whether there is a correlation between in vitro susceptibility of field isolates of Leishmania major and the clinical outcomes of meglumine antimoniate (Glucantime®) therapy, the mainstay of cutaneous leishmaniasis treatment in Iran. METHODS Forty-three patients infected with L. major were enrolled in this study from October 2009 to March 2010 and ...

The leishmanicidal activity of four batches of meglumine antimoniate, produced in Farmanguinhos-Fiocruz, Brazil (TAMs), was assessed and compared to Glucantime-Aventis Pharma Ltda. Using the amastigote-like in vitro model, the active concentrations of Sb v varied from 10microg/ml to 300microg/ml for L. (L.) chagasi and from 50microg/ml to 300microg/ml for L. (L.) amazonensis, with no statistica...

OBJECTIVES Intralesional injection of pentavalent antimoniate is recommended by the World Health Organization for the treatment of cutaneous leishmaniasis (CL). This study aimed to evaluate the adverse effects of intralesional injection of meglumine antimoniate (Glucantime(®) ) and its influence on clinical laboratory parameters. METHODS A total of 105 patients with suspected lesions and ther...

Visceral leishmaniasis (VL) affects over 500,000 people worldwide each year. The disease occurs in the Mediterranean basin, Central and South America and is caused by Leishmania infantum (syn L. chagasi). VL is an endemic disease in Colombia, particularly along the Caribbean coast and the Magdalena River Valley and 90% of VL cases occur in children under the age of five. The first line of treat...

BACKGROUND Recent circumstantial evidences are suggesting that an increasing number of Iranian patients with cutaneous leishmaniasis are unresponsive to meglumine antimoniate (Glucantime®). Pistacia atlantica is native plant in Iran (central, western, and eastern regions). Gum obtained Pistacia atlantica has been reported to possess considerable in vitro antimicrobial activity. In this study, w...

BACKGROUND & OBJECTIVES The mechanism of antimony resistance in Leishmania has been studied extensively, in connection with decreased influx and/or increased eflux of the drug. Aquaporin 1 (AQP1) protein has been shown to mediate the uptake of trivalent antimony. This study was aimed to find the expression level of AQP1 gene in resistant versus non-resistant clinical isolates of Leishmania majo...